Anika Therapeutics Inc. $ANIK Shares Purchased by Capital Management Corp VA

Capital Management Corp VA increased its holdings in Anika Therapeutics Inc. (NASDAQ:ANIK) by 24.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 408,845 shares of the biotechnology company’s stock after buying an additional 79,185 shares during the quarter. Capital Management Corp VA’s holdings in Anika Therapeutics were worth $4,326,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in shares of Anika Therapeutics by 4,714.3% in the 1st quarter. GAMMA Investing LLC now owns 6,403 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 6,270 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in Anika Therapeutics by 38.4% during the first quarter. Envestnet Asset Management Inc. now owns 95,634 shares of the biotechnology company’s stock valued at $1,437,000 after purchasing an additional 26,557 shares during the period. Cerity Partners LLC acquired a new position in Anika Therapeutics during the first quarter valued at $443,000. Noesis Capital Mangement Corp purchased a new stake in Anika Therapeutics in the first quarter valued at $292,000. Finally, Cetera Investment Advisers acquired a new stake in Anika Therapeutics during the 1st quarter worth about $152,000. 91.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Barrington Research reissued an “outperform” rating and issued a $15.00 price objective on shares of Anika Therapeutics in a report on Tuesday, September 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Anika Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $18.00.

Anika Therapeutics Stock Up 0.5%

NASDAQ:ANIK opened at $9.15 on Wednesday. Anika Therapeutics Inc. has a 52 week low of $7.87 and a 52 week high of $25.63. The stock has a market capitalization of $131.92 million, a PE ratio of -2.20 and a beta of 0.62. The stock’s 50-day moving average price is $8.94 and its 200-day moving average price is $11.00.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.